Life Sciences & Healthcare

Australian-Based Immutep Ltd Receives $3.63M AUD from French R&D Tax Incentive

June 11th, 2020

Sydney-based company Immutep Ltd has recently announced that it received a €2,173,454 (~A$3,630,000) R&D Tax Incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The payment relates to activity the company is conducting in Paris to develop its novel Immunotherapy treatment. Immutep Ltd also registers activities under the Australian R&D Tax Incentive and has previously reported the following receipts: YE 30 June 2018 – $872,000; YE 30 June 2019 – $1,290,000. Whilst there is […]

Read More

CSL Moves Up International Biotech Market Capitalisation Rankings Driven By R&D Investment

January 20th, 2020

A report in the Australian Financial Review has highlighted the remarkable performance of CSL over recent years, largely due to the company’s investment in R&D Activity. The report has highlighted: CSL’s share price has increased more than 50% during 2019, which is rare for a company of such size and maturity; If CSL maintains their current trajectory, it may shortly overtake Commonwealth Bank of Australia as the 2nd most valuable stock on the ASX by market capitalisation; CSL is now […]

Read More

Global Veterinary Surgical Instrument Projected Growth due to R&D Incentives

April 8th, 2019

A study involving some of the biggest veterinary surgical instruments manufacturers predicts a growth of approximately 6.5% during the forecast period 2018- 2023.   The growth is as a result of the rise in R&D expenditure, product innovation and demands in pet care on a global scale as the market is increasing going more competitive. Per a geological analysis, North America is expected to be on the forefront of this market followed by Europe. Asia- pacific will be expected to […]

Read More

Australia’s Attractiveness for Clinical Trials

March 6th, 2019

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Read More

Email this job

[recaptcha]